血管加压素启动阈值对脓毒性休克死亡率的影响:VASSPR整群交叉随机策略试验
该整群随机交叉实用性试验在13家医院比较脓毒性休克中低阈值(去甲肾上腺素等效0.1 µg/kg/min)与高阈值(0.4 µg/kg/min)启动血管加压素对28天死亡率的影响。
要点
- 低阈值启动血管加压素未降低脓毒性休克28天死亡率。
- 两组肾脏替代治疗无天数无显著差异。
- 低阈值策略下更多患者接受血管加压素(68.0% vs 42.7%)。
核心结论
- 在脓毒性休克中,推荐低剂量其他血管加压素时启动血管加压素的医院级策略未降低28天死亡率。
研究设计与样本
- 整群随机、整群交叉、实用性临床策略试验,纳入13家医院成人脓毒性休克接受血管加压素治疗的患者。
- 共纳入3959例独特患者,中位年龄68岁(IQR 57-77),女性1903例(48%)。
- 医院首月随机分配至低阈值(6家)或高阈值(7家)策略,此后每月交叉至替代策略。
主要发现
- 低阈值策略组28天死亡628/1975例(31.8%),高阈值策略组655/1984例(33.0%)。
- 肾脏替代治疗无天数中位均为29天(IQR -1至29),调整边际比值比1.01(95%CI 0.91-1.14)。
- 在最大血管加压素剂量≥0.07 µg/kg/min去甲肾上腺素等效的患者中,低阈值策略组1034/1521例(68.0%)接受血管加压素,高阈值组651/1526例(42.7%)。
- 低阈值策略组启动血管加压素前最大血管加压素剂量中位0.14(IQR 0.10-0.22)µg/kg/min去甲肾上腺素等效,高阈值组0.34(IQR 0.16-0.42)µg/kg/min。
关键数值与推荐
- 低阈值策略推荐当其他血管加压素总剂量达0.1 µg/kg/min去甲肾上腺素等效时启动固定剂量血管加压素。
- 高阈值策略推荐当其他血管加压素总剂量达0.4 µg/kg/min去甲肾上腺素等效时启动固定剂量血管加压素。
临床怎么用
- 对于脓毒性休克患者,较低剂量阈值启动血管加压素未显示生存获益,临床决策需综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The optimal vasopressor dose at which to initiate a second vasopressor in patients with septic shock is uncertain. OBJECTIVE: To compare the effects of hospital-level strategies initiating vasopressin infusion at a lower threshold vs a higher threshold on outcomes in patients with septic shock. DESIGN, SETTING, AND PARTICIPANTS: Cluster-randomized, cluster-crossover, pragmatic clinical strategy trial including adult patients receiving vasopressors for septic shock at 13 hospitals in Idaho and Utah from February 1, 2024, to July 31, 2025. The last day of follow-up for the primary outcome was February 17, 2026. INTERVENTION: Hospital-level implementation of septic shock management strategies recommending fixed-dose vasopressin initiation when the total dose of other vasopressors reached 0.1 µg/kg/min of norepinephrine or equivalent (lower-threshold strategy) or when the total dose of other vasopressors reached 0.4 µg/kg/min of norepinephrine or equivalent (higher-threshold strategy). Hospitals were randomized for the first month to an initial strategy (6 hospitals to the lower threshold vs 7 hospitals to the higher threshold) and then crossed over to the alternate strategy monthly thereafter. MAIN OUTCOMES AND MEASURES: The primary outcome of 28-day mortality and the key secondary outcome of kidney replacement therapy-free days through day 28 were analyzed using multivariable generalized linear mixed-effects models, accounting for trial site and baseline patient characteristics. RESULTS: There were 3959 unique patients with septic shock (median age, 68 [IQR, 57 to 77] years; 1903 [48%] were female). Of the patients more likely to experience differential management under the tested hospital-level vasopressin dose strategies (maximum vasopressor dose ≥0.07 µg/kg/min of norepinephrine or equivalent), 1034 of 1521 (68.0%) cared for under the lower-threshold strategy received vasopressin compared with 651 of 1526 (42.7%) cared for under the higher-threshold strategy. In the hospital-level strategy recommending a lower-dose threshold for vasopressin initiation, the maximum vasopressor dose received prior to vasopressin initiation was a median of 0.14 (IQR, 0.10 to 0.22) µg/kg/min of norepinephrine or equivalent vs 0.34 (IQR, 0.16 to 0.42) µg/kg/min of norepinephrine or equivalent in the hospital-level strategy recommending a higher-dose threshold for vasopressin initiation. Mortality at 28 days occurred in 628 of 1975 patients (31.8%) treated with the hospital-level strategy recommending initiation of vasopressin at a lower-dose threshold of other vasopressors vs 655 of 1984 patients (33.0%) treated with the higher-threshold strategy (adjusted marginal odds ratio, 0.98 [95% CI, 0.87 to 1.06], P = .62; adjusted risk difference, -0.4 [95% CI, -2.7 to 1.3] percentage points). Patients in both strategies for vasopressin initiation had a median of 29 (IQR, -1 to 29) kidney replacement therapy-free days (adjusted marginal odds ratio, 1.01 [95% CI, 0.91 to 1.14]). CONCLUSIONS AND RELEVANCE: In this large, pragmatic clinical trial comparing the effectiveness of 2 hospital-level strategies for second-line vasopressor management in septic shock, a strategy recommending initiation of vasopressin at a lower dose of other vasopressors did not reduce 28-day mortality compared with a strategy recommending vasopressin initiation at a higher dose of other vasopressors. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06217562.
引用
- Peltan ID, Groat D, Jacobs JR, et al. Effect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial. JAMA. 2026. PMID: 42872917. doi:10.1001/jama.2026.21333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。